



## **AgiOS to Present Updated Data from the Phase 1 Study of Vorasidenib in Non-enhancing Glioma in Oral Presentation at the American Society of Clinical Oncology Annual Meeting**

May 13, 2020

### **– Company to Present Additional Clinical Data Supporting Utility of TIBSOVO® in Cholangiocarcinoma and AML –**

CAMBRIDGE, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that vorasidenib and ivosidenib clinical data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting being held virtually May 29-31, 2020.

The accepted abstracts are listed below and are available online on the ASCO meeting library website: <https://meetinglibrary.asco.org/>. All oral and poster presentations will be available on demand for registered meeting attendees on the ASCO conference website beginning on May 29 at 8:00 a.m. ET.

#### **Oral Presentation:**

**Title:** Vorasidenib (VOR; AG-881), an inhibitor of mutant IDH1 and IDH2, in patients (pts) with recurrent/progressive glioma: Updated results from the phase I non-enhancing glioma population

**Oral Abstract Session:** Central Nervous System Tumors

**Abstract:** 2504

**Presenter:** Ingo K. Mellinghoff, M.D., Memorial Sloan Kettering Cancer Center

#### **Poster Presentations:**

**Title:** INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation

**Poster Session:** Central Nervous System Tumors

**Abstract:** TPS2574

**Author:** Ingo K. Mellinghoff, M.D., Memorial Sloan Kettering Cancer Center

**Title:** IDH1 mutation detection in plasma circulating tumor DNA (ctDNA) and association with clinical response in patients with advanced intrahepatic cholangiocarcinoma (IHC) from the phase III ClarIDHy study

**Poster Session:** Gastrointestinal Cancer – Gastroesophageal, Pancreatic, and Hepatobiliary

**Abstract:** 4576

**Author:** Elia Aguado-Fraile, Ph.D., Agios Pharmaceuticals

**Title:** Ivosidenib (IVO) prior to hematopoietic cell transplant for patients with IDH1-mutant relapsed or refractory acute myeloid leukemia (R/R AML)

**Poster Session:** Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allogeneic Transplant

**Abstract:** 7521

**Author:** Courtney D. DiNardo, M.D., University of Texas MD Anderson Cancer Center

#### **About Agios**

Agios is focused on discovering and developing novel investigational medicines to treat malignant hematology, solid tumors and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across these three therapeutic areas, Agios has two approved oncology precision medicines and multiple first-in-class investigational therapies in clinical and/or preclinical development. For more information, please visit the company's website at [www.agios.com](http://www.agios.com).

#### **Cautionary Note Regarding Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the potential benefits of TIBSOVO® (ivosidenib) and vorasidenib; Agios' plans regarding future data presentations; and the potential benefit of its strategic plans and focus. The words "anticipate," "expect," "intend," "potential," "milestone," "goal," "will," "on track," "upcoming," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from Agios' current expectations and beliefs. For example, there can be no guarantee that any product candidate Agios or its collaborators is developing will successfully commence or complete necessary preclinical and clinical development phases, or that development of any of Agios' product candidates will successfully continue. Moreover, there can be no guarantee that the two approved oncology precision medicines being commercialized by Agios and its collaborators will receive commercial acceptance. There can be no guarantee that any positive developments in Agios' business will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other important factors, including, without limitation: risks and uncertainties related to the impact of the COVID-19 pandemic to Agios' business, operations, strategy, goals and anticipated milestones, including its ongoing and planned research activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or future approved products, and launching, marketing and selling current or future approved products; Agios' results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. FDA, the EMA or other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies; Agios' ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials; unplanned cash requirements and expenditures; competitive factors; Agios' ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing; Agios' ability to maintain key collaborations; and general economic and market

conditions. These and other risks are described in greater detail under the caption "Risk Factors" included in Agios' public filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Agios expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

#### **Contacts**

##### **Investors:**

Holly Manning, 617-844-6630

Director, Investor Relations

[Holly.Manning@agios.com](mailto:Holly.Manning@agios.com)

##### **Media:**

Jessica Rennekamp, 857-209-3286

Associate Director, Corporate Communications

[Jessica.Rennekamp@agios.com](mailto:Jessica.Rennekamp@agios.com)



Source: Agios Pharmaceuticals, Inc.